Proton pump inhibitors and risk of incident CKD and progression to ESRD

Journal of the American Society of Nephrology

Volumn 27, Issue 10, 2016, Pages 3153-3163

  Xie, Yan ^a   Bowe, Benjamin ^a   Li, Tingting ^b   Xian, Hong ^a,c   Balasubramanian, Sumitra ^a   Al Aly, Ziyad ^a,b  

^a Veterans Affairs Saint Louis Health Care System   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SAINT LOUIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; CREATININE; ESOMEPRAZOLE; FAMOTIDINE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; COMPARATIVE STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE COURSE; END STAGE RENAL DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INTERSTITIAL NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; PROPENSITY SCORE; RISK FACTOR; TREATMENT DURATION; CHEMICALLY INDUCED; COMPLICATION; RETROSPECTIVE STUDY; RISK ASSESSMENT;

DISEASE PROGRESSION; FEMALE; HISTAMINE H2 ANTAGONISTS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 85011431641     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2015121377     Document Type: Article

References (54)

1. Antoniou T,Macdonald EM, Hollands S, Gomes T,MamdaniMM, Garg AX, Paterson JM, Juurlink DN: Proton pump inhibitors and the risk of acute kidney injury in older patients: A population-based cohort study. CMAJ Open 3: E166-E171, 2015
2. Klepser DG, Collier DS, Cochran GL: Proton pump inhibitors and acute kidney injury: A nested case-control study. BMC Nephrol 14: 150, 2013
3. Blank ML, Parkin L, Paul C, Herbison P: A nationwide nested casecontrol study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int 86: 837-844, 2014
4. Praga M, González E: Acute interstitial nephritis. Kidney Int 77: 956-961, 2010
5. Brewster UC, Perazella MA: Proton pump inhibitors and the kidney: critical review. Clin Nephrol 68: 65-72, 2007
6. Perazella MA, Markowitz GS: Drug-induced acute interstitial nephritis. Nat Rev Nephrol 6: 461-470, 2010
7. Rossert J: Drug-induced acute interstitial nephritis. Kidney Int 60: 804-817, 2001
8. Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, Grams ME: Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. JAMA Intern Med 176: 238-246, 2016
9. Schoenfeld AJ,GradyD: Adverse Effects Associated With Proton Pump Inhibitors. JAMA Intern Med 176: 172-174, 2016
10. Forgacs I, Loganayagam A: Overprescribing proton pump inhibitors. BMJ 336: 2-3, 2008
11. Choudhry, MN, Soran, H, Ziglam, HM: Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease. QJM 101: 445-448, 2008
12. Zink DA, Pohlman M, Barnes M, Cannon ME: Long-term use of acid suppression started inappropriately during hospitalization. Aliment Pharmacol Ther 21: 1203-1209, 2005
13. Strid H, Simrén M, Björnsson ES: Overuse of acid suppressant drugs in patients with chronic renal failure. Nephrol Dial Transplant 18: 570-575, 2003
14. Danziger J, William JH, Scott DJ, Lee J, Lehman LW, Mark RG, Howell MD, Celi LA,Mukamal KJ: Proton-pump inhibitor use is associated with low serum magnesium concentrations. Kidney Int 83: 692-699, 2013
15. Kieboom BC, Kiefte-de Jong JC, Eijgelsheim M, Franco OH, Kuipers EJ, Hofman A, Zietse R, Stricker BH, Hoorn EJ: Proton pump inhibitors and hypomagnesemia in the general population: A population-based cohort study. Am J Kidney Dis 66: 775-782, 2015
16. Behrman RE, Benner JS, Brown JS, McClellan M, Woodcock J, Platt R: Developing the Sentinel System-A national resource for evidence development. N Engl J Med 364: 498-499, 2011
17. Robb MA, Racoosin JA, Sherman RE, Gross TP, Ball R, Reichman ME, Midthun K, Woodcock J: The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety. Pharmacoepidemiol Drug Saf 21[Suppl 1]: 9-11, 2012
18. Psaty BM, Breckenridge AM: Mini-Sentinel and regulatory science-big data rendered fit and functional. N Engl J Med 370: 2165-2167, 2014
19. Hackam DG, Mamdani M, Li P, Redelmeier DA: Statins and sepsis in patients with cardiovascular disease: A population-based cohort analysis. Lancet 367: 413-418, 2006
20. Marincola FM: In support of descriptive studies; relevance to translational research. J Transl Med 5: 21, 2007
21. Härmark L, van der Wiel HE, de Groot MC, van Grootheest AC: Proton pump inhibitor-induced acute interstitial nephritis. Br J Clin Pharmacol 64: 819-823, 2007
22. PerazellaMA, Luciano RL: Review of select causes of drug-induced AKI. Expert Rev Clin Pharmacol 8: 367-371, 2015
23. Okusa MD, Chertow GM, Portilla D; Acute Kidney Injury Advisory Group of the American Society of Nephrology: The nexus of acute kidney injury, chronic kidney disease, andWorld Kidney Day 2009. Clin J Am Soc Nephrol 4: 520-522, 2009
24. Ishani A, Xue JL, Himmelfarb J, Eggers PW, Kimmel PL, Molitoris BA, Collins AJ: Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol 20: 223-228, 2009
25. Coca SG, Singanamala S, Parikh CR: Chronic kidney disease after acute kidney injury: A systematic review and meta-analysis. Kidney Int 81: 442-448, 2012
26. Van Laecke S, Nagler EV, Verbeke F, Van Biesen W, Vanholder R: Hypomagnesemia and the risk of death and GFR decline in chronic kidney disease. Am J Med 126: 825-831, 2013
27. Pham PC, Pham PM, Pham PA, Pham SV, Pham HV, Miller JM, Yanagawa N, Pham PT: Lower serum magnesium levels are associated with more rapid decline of renal function in patients with diabetes mellitus type 2. Clin Nephrol 63: 429-436, 2005
28. Pham PC, Pham PM, Pham PT, Pham SV, Pham PA, Pham PT: The link between lower serum magnesium and kidney function in patients with diabetes mellitus Type 2 deserves a closer look. Clin Nephrol 71: 375-379, 2009
29. Sakaguchi Y, Shoji T, Hayashi T, Suzuki A, Shimizu M, Mitsumoto K, Kawabata H, Niihata K, Okada N, Isaka Y, Rakugi H, Tsubakihara Y: Hypomagnesemia in type 2 diabetic nephropathy: A novel predictor of end-stage renal disease. Diabetes Care 35: 1591-1597, 2012
30. Holzmacher R, Kendziorski C, Michael Hofman R, Jaffery J, Becker B, Djamali A: Low serum magnesium is associated with decreased graft survival in patients with chronic cyclosporin nephrotoxicity. Nephrol Dial Transplant 20: 1456-1462, 2005
31. Tin A, GramsME,MaruthurNM, Astor BC, Couper D,Mosley TH, Selvin E, Coresh J, Kao WH: Results from the Atherosclerosis Risk in Communities study suggest that low serum magnesium is associated with incident kidney disease. Kidney Int 87: 820-827, 2015
32. Adams AL, Black MH, Zhang JL, Shi JM, Jacobsen SJ: Proton-pump inhibitor use and hip fractures inmen: A population-based case-control study. Ann Epidemiol 24: 286-290, 2014
33. Strom, BL: Pharmacoepidemiology, 2005.
34. Moride Y, Abenhaim L: Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol 47: 731-737, 1994
35. BrookhartMA,Wyss R, Layton JB, Stürmer T: Propensity score methods for confounding control in nonexperimental research. Circ Cardiovasc Qual Outcomes 6: 604-611, 2013
36. Stürmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S: A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol 59: 437-447, 2006
37. Winkelmayer WC, Kurth T: Propensity scores: help or hype? Nephrol Dial Transplant 19: 1671-1673, 2004
38. Xie Y, Bowe B, Xian H, Balasubramanian S, Al-Aly Z: Renal Function Trajectories in Patients with Prior Improved eGFR Slopes and Risk of Death. PLoS One 11: e0149283, 2016
39. Murphy PA, Cowper DC, Seppala G, Stroupe KT, Hynes DM: Veterans Health Administration inpatient and outpatient care data: an overview. Eff Clin Pract 5[Suppl]: E4, 2002
40. Oddone EZ, Eisen S: Veterans Affairs Research and Development: using science to improve health care for veterans.NCMed J 69: 35-37, 2008
41. VIReC Research User Guide: VHA Medical SAS Outpatient Datasets FY2006. U.S. Department of Veterans Affairs. VA Information Resource Center: Hines, I, September 2007
42. VIReC Research User Guide: VHA Medical SAS Inpatient Datasets FY2006. U.S. Department of Veterans Affairs. VA Information Resource Center: Hines, I, September 2007
43. Al-Aly Z: Prediction of renal end points in chronic kidney disease. Kidney Int 83: 189-191, 2013
44. Coresh J, Turin TC,Matsushita K, Sang Y, Ballew SH, Appel LJ, Arima H, Chadban SJ, CirilloM, DjurdjevO,Green JA,HeineGH, Inker LA, Irie F, Ishani A, Ix JH, Kovesdy CP, Marks A, Ohkubo T, Shalev V, Shankar A, Wen CP, de Jong PE, Iseki K, Stengel B, Gansevoort RT, Levey AS, Consortium CKDP; CKD Prognosis Consortium: Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 311: 2518-2531, 2014
45. BoweM, Xie Y, Xian H, Balasubramanian S, Al-Aly Z: Low levels of highdensity lipoprotein cholesterol increase the risk of incident kidney disease and its progression [published online ahead of print January 29, 2016]. Kidney international doi: 10.1016/j.kint.2015.12.034
46. Rahman M, Yang W, Akkina S, Alper A, Anderson AH, Appel LJ, He J, Raj DS, Schelling J, Strauss L, Teal V, Rader DJ, Investigators CS; CRIC Study Investigators: Relation of serum lipids and lipoproteins with progression of CKD: The CRIC study. Clin J Am Soc Nephrol 9: 1190-1198, 2014
47. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, Ckd EPI; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612, 2009
48. Gawron AJ, Pandolfino JE, Miskevics S, Lavela SL: Proton pump inhibitor prescriptions and subsequent use in US veterans diagnosed with gastroesophageal reflux disease. J Gen Intern Med 28: 930-937, 2013
49. Xie Y, Bowe B, Xian H, Balasubramanian S, Al-Aly Z: Rate of Kidney Function Decline and Risk of Hospitalizations in Stage 3A CKD. Clin J Am Soc Nephrol 10: 1946-1955, 2015
50. Xie Y, Bowe B, Xian H, Balasubramanian S, Al-Aly Z: Estimated GFR Trajectories of People Entering Stage 4 CKD and Subsequent Kidney Disease Outcomes and Mortality [publsihed online ahead of print March 4, 2016]. Am J Kidney Dis doi: 10.1053/j.ajkd.2016.02.039
51. Johnson ES, Bartman BA, Briesacher BA, Fleming NS, Gerhard T, Kornegay CJ, Nourjah P, Sauer B, Schumock GT, Sedrakyan A, Stürmer T, West SL, Schneeweiss S: The incident user design in comparative effectiveness research. Pharmacoepidemiol Drug Saf 22: 1-6, 2013
52. Austin PC: An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res 46: 399-424, 2011
53. Austin PC, Grootendorst P, Anderson GM: A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: A Monte Carlo study. Stat Med 26: 734-753, 2007
54. SiewED, Parr SK, Abdel-Kader K, Eden SK, Peterson JF, BansalN,Hung AM, Fly J, Speroff T, Ikizler TA, Matheny ME: Predictors of Recurrent AKI [published online ahead of print August 11, 2015]. J Am Soc Nephrol doi:ASN.2014121218